ABSTRACT
Neoadjuvant cisplatin-based chemotherapy (NAC; 70 mg/m2) is standard of care for muscle-invasive bladder carcinoma (MIBC). Many patients (pts) cannot receive cisplatin because of renal impairment, and administration of cisplatin 35 mg/m2 on day 1 + 8 or 1 + 2 (i.e., split schedule) is a commonly used alternative. In this retrospective analysis, we compared complete (pT0) and partial (Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage
, Carcinoma, Transitional Cell/therapy
, Cisplatin/administration & dosage
, Neoadjuvant Therapy/methods
, Urinary Bladder Neoplasms/therapy
, Aged
, Antineoplastic Combined Chemotherapy Protocols/adverse effects
, Carcinoma, Transitional Cell/pathology
, Cisplatin/adverse effects
, Cystectomy
, Female
, Humans
, Kidney/drug effects
, Male
, Neoadjuvant Therapy/adverse effects
, Neoplasm Invasiveness/pathology
, Neoplasm Staging
, Renal Insufficiency/chemically induced
, Renal Insufficiency/epidemiology
, Renal Insufficiency/prevention & control
, Retrospective Studies
, Treatment Outcome
, Urinary Bladder Neoplasms/pathology
